These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17167764)

  • 21. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma.
    Anderson P; Nuñez R
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1517-27. PubMed ID: 18020921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Our experience on pain palliation of bone metastasis with Sr-89 or Sm-153 in cancer patients resistant to a conventional analgesic therapy. A retrospective study.
    Montesano T; Giacomobono S; Acqualagna G; Colandrea M; Di Nicola A; Travascio L; Giancamerla M; D'Apollo R; Toteda M; Ugolini F; Filesi M; Ronga G
    Clin Ter; 2009; 160(3):193-9. PubMed ID: 19756320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases.
    Liepe K; Kotzerke J
    Nucl Med Commun; 2007 Aug; 28(8):623-30. PubMed ID: 17625384
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Myelotoxicity after systemic radionuclide therapy of painful bone metastases with 153Samarium-EDTMP ].
    Dolezal J; Vizd'a J; Cermáková E
    Vnitr Lek; 2003 Mar; 49(3):189-93. PubMed ID: 12728593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis.
    Serafini AN
    Q J Nucl Med; 2001 Mar; 45(1):91-9. PubMed ID: 11456381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Samarium 153Sm lexidronam.
    Lamb HM; Faulds D
    Drugs Aging; 1997 Nov; 11(5):413-8; discussion 419. PubMed ID: 9359026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cost-effectiveness of samarium-153-EDTMP for the treatment of pain due to multiple bone metastases in hormone-refractory prostate cancer versus conventional pain therapy, in Portugal].
    Macedo A; Araújo A; Melo FC; Nunes G; Cantinho G; Amorin I
    Acta Med Port; 2006; 19(5):421-6. PubMed ID: 17376329
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [153Sm-EDTMP for moderate and severe bone cancer pain].
    Deng H; Luo S; Tan T; Mo T; Liang Z; Pu M; Jiao J; Zhong S; Wang Q; Hu Y
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Dec; 26(4):391-4. PubMed ID: 8732058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases.
    Tripathi M; Singhal T; Chandrasekhar N; Kumar P; Bal C; Jhulka PK; Bandopadhyaya G; Malhotra A
    Indian J Cancer; 2006; 43(2):86-92. PubMed ID: 16790946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial.
    Collins C; Eary JF; Donaldson G; Vernon C; Bush NE; Petersdorf S; Livingston RB; Gordon EE; Chapman CR; Appelbaum FR
    J Nucl Med; 1993 Nov; 34(11):1839-44. PubMed ID: 8229221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases.
    Dolezal J
    Onkologie; 2009 Feb; 32(1-2):35-9. PubMed ID: 19209017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow recovery following use of systemic (153)Sm-lexidronam and (89)Sr-chloride for bone pain palliation after myelosuppressive therapy.
    Papatheofanis FJ; Najib MM
    Int J Radiat Biol; 2009 May; 85(5):448-53. PubMed ID: 19437245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP.
    Sinzinger H; Weiss K; Hiltunen J
    Anticancer Res; 2009 Aug; 29(8):3393-5. PubMed ID: 19661362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Analgesic response and secondary effects in patients with osteoblastic metastasis, treated with Samarium 153 ethylenediaminotetramethylenephosphate].
    Lovera C; Massardo T; Galleguillos MC; González P; Comparini B; Yáñez M; Fodor M; Gil MC; Araya G; Tomicic M
    Rev Med Chil; 1998 Aug; 126(8):963-71. PubMed ID: 9830748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
    Morris MJ; Pandit-Taskar N; Carrasquillo J; Divgi CR; Slovin S; Kelly WK; Rathkopf D; Gignac GA; Solit D; Schwartz L; Stephenson RD; Hong C; Delacruz A; Curley T; Heller G; Jia X; O'Donoghue J; Larson S; Scher HI
    J Clin Oncol; 2009 May; 27(15):2436-42. PubMed ID: 19364960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease.
    Coronado M; Redondo A; Coya J; Espinosa E; Couto RM; Zamora P; Marin MD; Castelo B; Lillo ME; Frutos L; Barón MG; Curto LM
    Clin Nucl Med; 2006 Oct; 31(10):605-10. PubMed ID: 16985364
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Samarium-153-EDTMP in bone metastases.
    Ahonen A; Joensuu H; Hiltunen J; Hannelin M; Heikkilä J; Jakobsson M; Jurvelin J; Kairemo K; Kumpulainen E; Kulmala J
    J Nucl Biol Med (1991); 1994 Dec; 38(4 Suppl 1):123-7. PubMed ID: 7543288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I trial of vertebral intracavitary cement and samarium (VICS): novel technique for treatment of painful vertebral metastasis.
    Ashamalla H; Cardoso E; Macedon M; Guirguis A; Weng L; Ali S; Mokhtar B; Ashamalla M; Panigrahi N
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):836-42. PubMed ID: 19362780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China.
    Tian JH; Zhang JM; Hou QT; Oyang QH; Wang JM; Luan ZS; Chuan L; He YJ
    Eur J Nucl Med; 1999 Jan; 26(1):2-7. PubMed ID: 9933654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improvement in sensory pain rating after palliative systemic radionuclide therapy in patients with advanced prostate cancer.
    Papatheofanis FJ; Smith C; Najib M
    Am J Ther; 2009; 16(2):127-32. PubMed ID: 19300039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.